These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 16585158)

  • 1. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
    Man S; Munoz R; Kerbel RS
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice.
    Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T
    Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
    Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Three cases of metastatic breast cancer, resistant to pre-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy].
    Ogawa Y; Ishikawa T; Ogisawa K; Ikeda K; Nagatsuka I; Matsumura Y; Takashima T; Yashiro M; Onoda N; Nakata B; Kato Y; Hirakawa K
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2123-7. PubMed ID: 11103246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer.
    Ogawa Y; Ishikawa T; Chung SH; Ikeda K; Takashima T; Onoda N; Nakata B; Nishiguchi Y; Hirakawa K
    Anticancer Res; 2003; 23(4):3453-7. PubMed ID: 12926089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
    Muñoz R; Hileeto D; Cruz-Muñoz W; Wood GA; Xu P; Man S; Viloria-Petit A; Kerbel RS
    PLoS One; 2019; 14(9):e0222580. PubMed ID: 31536574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiproliferative and antimetastatic effects of UFT on MKL-4 human breast cancer cells transplanted into nude mice].
    Kurebayashi J; Sonoo H
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):665-70. PubMed ID: 7717719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
    Ito Y; Nakanishi H; Kodera Y; Hirai T; Nakao A; Kato T
    Cancer Sci; 2010 Aug; 101(8):1853-60. PubMed ID: 20500514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.
    Uchida J; Okabe H; Nakano K; Fujioka A; Saito H; Sugimoto Y; Oka T; Fukushima M
    Oncol Rep; 2007 Aug; 18(2):313-9. PubMed ID: 17611650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
    Watanabe O; Shimizu T; Imamura H; Kinoshita J; Okabe T; Ogawa K; Haga S
    Gan To Kagaku Ryoho; 2004 May; 31(5):717-21. PubMed ID: 15170979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.